Moffitt Cancer Center

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized ...
read more ↘

 

17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
38:56

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Moffitt Cancer Center Debate on the Use of MRD to Guide Transplant Decisions in AML and MDS

FEATURING Hugo F. Fernandez, Nelli Bejanyan
  • 198 views
  • February 16, 2022
  • 2
31:09

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 Updates on BCMA CAR T-Cell for MM: Real World Experience and Future Perspectives

FEATURING Melissa Alsina
  • 138 views
  • February 14, 2022
  • 1
26:02

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 Novel Immune-Based Therapy for R/R MM: Interactive Case Discussion

FEATURING Jason Brayer
  • 195 views
  • February 14, 2022
  • 2
16:00

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Moffitt Cancer Center Debate: How Much Is Too Much in NDMM - Triplet Therapy vs. Quadruplet Therapy

FEATURING Rachid Baz
  • 85 views
  • February 14, 2022
  • 1
18:44

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Moffitt Cancer Center Debate: How Much Is Enough in NDMM - Triplet Therapy vs. Quadruplet Therapy

FEATURING Kenneth Shain
  • 147 views
  • February 14, 2022
  • 1
20:54

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 Updates on COVID-19 in Cancer Patients: Outcomes and Prevention

FEATURING Anna Giuliano
  • 21 views
  • February 14, 2022
  • 1
19:36

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Managing Hematologic Toxicities From Immunotherapeutic Agents

FEATURING Michael Jaglal
  • 192 views
  • February 14, 2022
  • 2
23:05

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Evaluation of Clonal Hematopoiesis in Patients With Solid Tumors: Case Discussion

FEATURING Eric Padron
  • 106 views
  • February 14, 2022
  • 1
22:37

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 Moffitt Cancer Center Updates on the Role of CAR T-Cells in Lymphomas

FEATURING Frederick Locke
  • 88 views
  • February 14, 2022
  • 1
26:22

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 State of the Art: Best Frontline Therapy for CLL

FEATURING Javier Pinilla-Ibarz
  • 483 views
  • February 14, 2022
  • 5
25:53

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Moffitt Cancer Center's Updates on Treatment of R/R DLBCL: Interactive Case Discussion

FEATURING Sameh Gaballa
  • 92 views
  • February 14, 2022
  • 1
34:29

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Moffitt Cancer Center Debate: Should NGS Be Reported in All Newly Diagnosed Lymphomas?

FEATURING Bijal Shah, Hayder Saeed
  • 68 views
  • February 14, 2022
27:27

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 State of the Art Frontline Management of the HR-MDS

FEATURING Rami Komrokji
  • 317 views
  • February 14, 2022
  • 2
22:48

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Using Molecular Monitoring to Guide Therapy in AML: Interactive Case Discussion

FEATURING Kendra Sweet
  • 105 views
  • February 14, 2022
  • 1